Fight for Your Right to Choose Safe, Effective Bio-Identical Hormones Urges Leading Gynecologist Dr. C.W. Randolph

Share Article

Wyeth is trying to take away your rights. More than 25,000 have registered their complaint to the FDA against Wyeth.

Fight for your right to choose safe, effective bio-identical hormones says leading gynecologist Dr. C.W. Randolph. Wyeth is trying to take away your rights.

More than 25,000 have registered their complaint to the FDA against Wyeth. The FDA is expected to rule on this decision after the April 4 comment deadline this week. Wyeth Pharmaceutical is urging the FDA to take away your right to choose safe, effective and natural, bio-identical hormones by regulating your choice of health treatments.

C.W. Randolph, Jr., M. D. R. Ph., one of the nation’s leading bio-identical hormone physicians, says Wyeth Pharmaceuticals must be stopped.

“The growing popularity of bio-identical hormone therapy and the decline in sales for Wyeth Pharmaceuticals has prompted them to try to deny a woman’s right to choose,” said Dr. C.W. Randolph, best selling author of “From Hormone Hell to Hormone Well.”

Wyeth, the maker of Premarin and Prempro, filed a "Citizens Complaint" with the FDA on October 16, 2005, requesting that the FDA effectively prohibit compounding pharmacies from providing bio-identical hormones to their patients.

Since the 2002 Women's Health Initiative (WHI) which demonstrated that Wyeth's products, Premarin and Prempro, caused a significant increase in breast cancer, blood clots to the lungs, heart attacks and strokes, Wyeth has seen a dramatic decline in the sales of these counterfeit hormones. Wyeth's financial reports, which are available online at, indicate the following significant decline in sales of Premarin Family products; 2002 - $2,072,000,000; 2003 - $1,275,000,000; 2004 - $880,000,000.

This represents a 68% decline in sales of Premarin Family products between 2002 - 2004. Wyeth's profits have likewise declined precipitously; 2002 - $4,447,000,000; 2003 - $2,051,192,000; 2004 - $1,234,000,000, a 72% decline in profits.

Randolph says, that Wyeth is using lobbyists to influence the FDA to prevent women from using natural safe options for hormone balance.

“Bio-identical hormones are safe and effective, relieving the symptoms of hormonal imbalances without the potentially life-threatening side effects of chemical drugs like Premarin,” said Randolph. “Wyeth wants to make it illegal for us to use compounded (individually prepared) pills and creams from natural "bio-identical" sources.”

“Wyeth wants to force women to take their counterfeit hormones by eliminating the competition from bio-identical hormones prepared by compounding pharmacies,” said Randolph.

The FDA collects no drug user fees from compounding pharmacies because they are regulated by the states, not the federal government. The FDA does receive drug user fees, totaling over $300,000,000 in 2004, from the pharmaceutical companies for the drugs they sell. The fewer drugs that Wyeth sells, the less money the FDA makes. Dr. Randolph feels that the FDA wants to eliminate compounding pharmacies as well.

Wyeth, like all the major pharmaceutical companies, contributes billions of dollars to various medical societies and patient advocacy organizations. So it is not surprising that many of these organizations have written responses to the FDA in support of Wyeth's complaint.

More than 25,000 bio-identical supporters have voiced their complaint directly to the FDA. The comment filing period ends this week and the FDA is scheduled to make it’s decision very soon.

Randolph urges that blocking Wyeth’s plan to eliminate bio-identical hormones is crucial to an American’s right to choose.

Some consumers who have been so upset by Wyeth Pharmaceutical’s actions in this area that they have started to boycott their Wyeth products such as: Advil, Alavert, Anbesol, Centrum Vitamins, Chap Stick, Dimetapp, FiberCon, Primatene, and Robitussin.

To set up an interview with Dr. Randolph, please contact Nanette Noffsinger at 615-776-4230.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nanette Noffsinger
Visit website